cilengitide

Also known as EMD-12192, EMD-121974

Cilengitide (EMD 121974) is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt. It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for αv integrins, which are important in angiogenesis (forming new blood vessels), and other aspects of tumor biology. Hence, it is under investigation for the treatment of glioblastoma, where it may act by inhibiting angiogenesis, and influencing tumor invasion and proliferation.

Research

411 papers

Cilengitide Merck.Current opinion in investigational drugs (London, England : 2000) · 2003
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.Expert opinion on investigational drugs · 2008
Cilengitide sensitivity is predicted by overall integrin expression in breast cancer.Breast cancer research : BCR · 2024
Cilengitide inhibits osteoclast adhesion through blocking the α(v)β(3)-mediated FAK/Src signaling pathway.Heliyon · 2023
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.Anti-cancer agents in medicinal chemistry · 2010

via PubMed

Wikidata facts

Mass: 588.302

Show 3 more facts

chemical formula: C₂₇H₄₀N₈O₇
canonical SMILES: CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
isomeric SMILES: CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N

Sources (2)

via Wikidata · CC0

~3 min read

Article

2 sections

Contents

Clinical trials
References

{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 460036937 | ImageFile = Cilengitide.svg | ImageClass = skin-invert-image | ImageSize = 300px | IUPACName = 2-[(2S,5R,8S,11S)-5-benzyl-11-{3-[(diaminomethylidene)amino]propyl}-7-methyl-3,6,9,12,15-pentaoxo-8-(propan-2-yl)-1,4,7,10,13-pentaazacyclopentadecan-2-yl]acetic acid | OtherNames = |Section1= |Section2= |Section3= }} Cilengitide (EMD 121974) is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt. It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for αv integrins, which are important in angiogenesis (forming new blood vessels), and other aspects of tumor biology. Hence, it is under investigation for the treatment of glioblastoma, where it may act by inhibiting angiogenesis, and influencing tumor invasion and proliferation.

The European Medicines Agency has granted cilengitide orphan drug status.